Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07469774) titled 'BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors' on March 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Biocity Biopharmaceutics Co., Ltd.

Condition: Locally Advanced or Metastatic Solid Tumors

Intervention: Drug: BC3195

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: March 17, 2026

Target Sample Size: 111

Countries of Recruitment: China

To know more, visit https://clinicaltria...